# Glaukos to acquire DOSE Medical for $2.5M plus milestones

Glaukos Corporation entered into a definitive agreement to acquire DOSE Medical Corporation for $2.5 million in cash plus performance-based consideration. DOSE Medical develops sustained-release drug delivery platforms for retinal diseases. The transaction is expected to close in the current quarter.

- Type: Acquisition
- Announced: 2019-06-19
- Where: United States
- Value: $2.50M
- Status: announced
- Products: bioerodible sustained-release drug delivery platforms
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Glaukos Corporation](https://endata.com/companies/39036.md) (acquirer)
- [DOSE Medical Corporation](https://endata.com/companies/40091.md) (target)

## Sources

- [investors.glaukos.com](https://investors.glaukos.com/news/news-details/2019/Glaukos-Corporation-Enters-into-Definitive-Agreement-to-Acquire-DOSE-Medical-Corporation/default.aspx), 2019-06-19: "With this acquisition, Glaukos will establish a new R&D retinal program that complements our growing glaucoma franchise and pipeline."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.